Alexza Amends Autoliv Agreement for Heat Packages Used in ADASUVE

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that it amended its commercial Manufacturing and Supply Agreement ("Supply Agreement") with Autoliv ASP Inc., the North American subsidiary of Sweden-based Autoliv Inc. Autoliv manufactures chemical heat packages, a key component of Alexza's single-dose Staccato® system, including Alexza's commercial product ADASUVE (Staccato loxapine). The amendment to the Supply Agreement between Alexza and Autoliv, signed on December 12, 2014, updates certain terms of prior agreements between the companies. The Amendment states that the letter of termination received by Alexza in October 2013 is null, and that the parties are extending the agreement through 2018. In addition, Alexza has the right to engage a second source supplier and implement a manufacturing line transfer from Autoliv to manufacture and supply the chemical heat packages to Alexza or its licensees. "The amended agreement extends our ongoing partnership with Autoliv, providing us with continued supply of this key component, while enabling Alexza the flexibility to engage another supplier as an alternate source of supply for heat packages," said Robert A. Lippe, Executive Vice President, Operations and Chief Operations Officer of Alexza. "We appreciate and value Autoliv's operational excellence, cost efficiency, and technological capabilities in manufacturing and scaled production. We look forward to continuing to work with Autoliv as it supplies heat packages in support of the expanding global launch of ADASUVE."